Kinome profiling identifies MARK3 and STK10 as potential therapeutic targets in uveal melanoma
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Kinome profiling identifies MARK3 and STK10 as potential therapeutic targets in uveal melanoma
Authors
Keywords
-
Journal
JOURNAL OF BIOLOGICAL CHEMISTRY
Volume -, Issue -, Pages 105418
Publisher
Elsevier BV
Online
2023-11-04
DOI
10.1016/j.jbc.2023.105418
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The metabolic stress-activated checkpoint LKB1-MARK3 axis acts as a tumor suppressor in high-grade serous ovarian carcinoma
- (2022) Hidenori Machino et al. Communications Biology
- The future of targeted kinase inhibitors in melanoma
- (2022) Signe Caksa et al. PHARMACOLOGY & THERAPEUTICS
- Synthetic Lethal Screens Reveal Co-Targeting FAK and MEK as a Multimodal Precision Therapy for GNAQ-Driven Uveal Melanoma
- (2021) Justine S. Paradis et al. CLINICAL CANCER RESEARCH
- Discovery of a Potent Dual SLK/STK10 Inhibitor Based on a Maleimide Scaffold
- (2021) Ricardo A. M. Serafim et al. JOURNAL OF MEDICINAL CHEMISTRY
- Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
- (2021) Paul Nathan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Functional proteomics interrogation of the kinome identifies MRCKA as a therapeutic target in high-grade serous ovarian carcinoma
- (2020) Alison M. Kurimchak et al. Science Signaling
- Metabolic adaptations to MEK and CDK4/6 co-targeting in uveal melanoma
- (2020) Jessica LF Teh et al. MOLECULAR CANCER THERAPEUTICS
- Combined Inhibition of Gαq and MEK Enhances Therapeutic Efficacy in Uveal Melanoma
- (2020) Tyler D. Hitchman et al. CLINICAL CANCER RESEARCH
- BAP1 mutant uveal melanoma is stratified by metabolic phenotypes with distinct vulnerability to metabolic inhibitors
- (2020) Anna Han et al. ONCOGENE
- Functional characterization of uveal melanoma oncogenes
- (2020) Jiafang Ma et al. ONCOGENE
- Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma
- (2019) Vivian Chua et al. EMBO Molecular Medicine
- Mapping the Human Kinome in Response to DNA Damage
- (2019) Michel Owusu et al. Cell Reports
- A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK
- (2019) Xiaodong Feng et al. CANCER CELL
- PCC0208017, a novel small-molecule inhibitor of MARK3/MARK4, suppresses glioma progression in vitro and in vivo
- (2019) Fangfang Li et al. Acta Pharmaceutica Sinica B
- Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)
- (2018) Richard D. Carvajal et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of Oncogenic Gαq and Gα11 Inhibition by FR900359 in Uveal Melanoma
- (2018) Dominic Lapadula et al. MOLECULAR CANCER RESEARCH
- GENCODE reference annotation for the human and mouse genomes
- (2018) Adam Frankish et al. NUCLEIC ACIDS RESEARCH
- Dysregulated GPCR Signaling and Therapeutic Options in Uveal Melanoma
- (2017) Vivian Chua et al. MOLECULAR CANCER RESEARCH
- Kinome-wide transcriptional profiling of uveal melanoma reveals new vulnerabilities to targeted therapeutics
- (2017) Fiona P. Bailey et al. Pigment Cell & Melanoma Research
- Metastatic disease from uveal melanoma: treatment options and future prospects
- (2016) Richard D Carvajal et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Hippo-Independent Activation of YAP by the GNAQ Uveal Melanoma Oncogene through a Trio-Regulated Rho GTPase Signaling Circuitry
- (2014) Xiaodong Feng et al. CANCER CELL
- Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma
- (2014) Richard D. Carvajal et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- ERM proteins in cancer progression
- (2014) J. Clucas et al. JOURNAL OF CELL SCIENCE
- Inhibition of Mutant GNAQ Signaling in Uveal Melanoma Induces AMPK-Dependent Autophagic Cell Death
- (2013) G. Ambrosini et al. MOLECULAR CANCER THERAPEUTICS
- A genetic screen identifies an LKB1–MARK signalling axis controlling the Hippo–YAP pathway
- (2013) Morvarid Mohseni et al. NATURE CELL BIOLOGY
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- STAR: ultrafast universal RNA-seq aligner
- (2012) Alexander Dobin et al. BIOINFORMATICS
- Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer
- (2012) James S. Duncan et al. CELL
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
- (2011) Bo Li et al. BMC BIOINFORMATICS
- LOK is a major ERM kinase in resting lymphocytes and regulates cytoskeletal rearrangement through ERM phosphorylation
- (2009) N. V. Belkina et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Molecular Pathways Mediating Liver Metastasis in Patients with Uveal Melanoma
- (2008) S. Bakalian et al. CLINICAL CANCER RESEARCH
- Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi
- (2008) Catherine D. Van Raamsdonk et al. NATURE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search